S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:BABYNatus Medical Competitors & Alternatives

Notice: This company has been marked as potentially delisted and may not be actively trading.
$21.10
-0.13 (-0.61 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.82
Now: $21.10
$21.37
50-Day Range
$26.75
MA: $29.96
$31.92
52-Week Range
$23.53
Now: $21.10
$37.90
Volume134,500 shs
Average Volume165,325 shs
Market Capitalization$717.61 million
P/E Ratio14.86
Dividend YieldN/A
Beta0.57

Competitors

Natus Medical (NASDAQ:BABY) Vs. ABT, MDT, BDX, ISRG, SYK, and BSX

Should you be buying BABY stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Natus Medical, including Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Abbott Laboratories and Natus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories241302.58
Natus Medical0000N/A

Abbott Laboratories presently has a consensus price target of $100.2667, indicating a potential upside of 3.66%. Given Abbott Laboratories' higher probable upside, research analysts plainly believe Abbott Laboratories is more favorable than Natus Medical.

Valuation & Earnings

This table compares Abbott Laboratories and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.36$3.69 billion$3.2429.85
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Abbott Laboratories has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories11.15%18.61%8.61%
Natus Medical-7.38%10.79%6.57%

Volatility and Risk

Abbott Laboratories has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Insider and Institutional Ownership

73.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 91.6% of Natus Medical shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 1.7% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats Natus Medical on 12 of the 13 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Valuation & Earnings

This table compares Medtronic and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion4.39$4.79 billion$4.5920.62
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Medtronic has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Medtronic has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Insider and Institutional Ownership

81.0% of Medtronic shares are owned by institutional investors. Comparatively, 91.6% of Natus Medical shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 1.7% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and Natus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic162212.77
Natus Medical0000N/A

Medtronic presently has a consensus price target of $114.5333, indicating a potential upside of 21.01%. Given Medtronic's higher probable upside, research analysts plainly believe Medtronic is more favorable than Natus Medical.

Profitability

This table compares Medtronic and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic16.56%12.17%6.79%
Natus Medical-7.38%10.79%6.57%

Summary

Medtronic beats Natus Medical on 12 of the 14 factors compared between the two stocks.

Becton Dickinson and (NYSE:BDX) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Becton Dickinson and and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton Dickinson and$17.29 billion4.19$1.23 billion$11.6822.86
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Becton Dickinson and has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Becton Dickinson and has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

85.4% of Becton Dickinson and shares are held by institutional investors. Comparatively, 91.6% of Natus Medical shares are held by institutional investors. 0.1% of Becton Dickinson and shares are held by insiders. Comparatively, 1.7% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Becton Dickinson and and Natus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton Dickinson and07902.56
Natus Medical0000N/A

Becton Dickinson and presently has a consensus price target of $277.0667, indicating a potential upside of 3.79%. Given Becton Dickinson and's higher probable upside, equities analysts plainly believe Becton Dickinson and is more favorable than Natus Medical.

Profitability

This table compares Becton Dickinson and and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton Dickinson and6.10%15.75%6.37%
Natus Medical-7.38%10.79%6.57%

Summary

Becton Dickinson and beats Natus Medical on 10 of the 13 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Intuitive Surgical and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion15.83$1.38 billion$9.9561.09
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Intuitive Surgical has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Intuitive Surgical has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

87.2% of Intuitive Surgical shares are held by institutional investors. Comparatively, 91.6% of Natus Medical shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by insiders. Comparatively, 1.7% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Intuitive Surgical and Natus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical461302.39
Natus Medical0000N/A

Intuitive Surgical presently has a consensus price target of $577.1667, indicating a potential downside of 5.04%. Given Intuitive Surgical's higher probable upside, equities analysts plainly believe Intuitive Surgical is more favorable than Natus Medical.

Profitability

This table compares Intuitive Surgical and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical30.11%17.40%14.87%
Natus Medical-7.38%10.79%6.57%

Summary

Intuitive Surgical beats Natus Medical on 11 of the 13 factors compared between the two stocks.

Stryker (NYSE:SYK) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Stryker and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion4.75$2.08 billion$8.2622.84
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Stryker has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stryker has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

71.2% of Stryker shares are held by institutional investors. Comparatively, 91.6% of Natus Medical shares are held by institutional investors. 6.8% of Stryker shares are held by insiders. Comparatively, 1.7% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Stryker and Natus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker271612.62
Natus Medical0000N/A

Stryker presently has a consensus price target of $215.20, indicating a potential upside of 14.09%. Given Stryker's higher probable upside, equities analysts plainly believe Stryker is more favorable than Natus Medical.

Profitability

This table compares Stryker and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker14.47%24.90%11.10%
Natus Medical-7.38%10.79%6.57%

Summary

Stryker beats Natus Medical on 13 of the 14 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Natus Medical (NASDAQ:BABY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Boston Scientific and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.78$4.70 billion$1.5823.23
Natus Medical$530.89 million1.35$-22,930,000.00$1.4214.86

Boston Scientific has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Boston Scientific has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

90.0% of Boston Scientific shares are held by institutional investors. Comparatively, 91.6% of Natus Medical shares are held by institutional investors. 0.7% of Boston Scientific shares are held by insiders. Comparatively, 1.7% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Boston Scientific and Natus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific021933.04
Natus Medical0000N/A

Boston Scientific presently has a consensus price target of $44.6522, indicating a potential upside of 21.67%. Given Boston Scientific's higher probable upside, equities analysts plainly believe Boston Scientific is more favorable than Natus Medical.

Profitability

This table compares Boston Scientific and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific39.75%18.24%7.64%
Natus Medical-7.38%10.79%6.57%

Summary

Boston Scientific beats Natus Medical on 11 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.1$96.73-2.0%$171.10 billion$31.90 billion48.61Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.9$94.65-2.0%$130.32 billion$28.91 billion26.66
Becton Dickinson and logo
BDX
Becton Dickinson and
2.0$266.96-1.3%$72.39 billion$17.29 billion80.41Analyst Report
Insider Selling
Heavy News Reporting
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$607.80-3.7%$70.88 billion$4.48 billion52.35Upcoming Earnings
Analyst Report
Heavy News Reporting
Stryker logo
SYK
Stryker
2.3$188.62-3.1%$70.70 billion$14.88 billion33.15
Boston Scientific logo
BSX
Boston Scientific
2.1$36.70-4.0%$51.36 billion$10.74 billion12.07
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.7$71.22-5.7%$44.91 billion$4.35 billion40.85Analyst Report
Insider Selling
Heavy News Reporting
Baxter International logo
BAX
Baxter International
2.0$84.65-1.4%$44.17 billion$11.36 billion25.57Dividend Announcement
DexCom logo
DXCM
DexCom
1.5$417.94-1.8%$38.59 billion$1.48 billion262.86Insider Selling
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.3$338.47-1.0%$28.94 billion$2.41 billion67.69
ResMed logo
RMD
ResMed
1.2$195.04-3.6%$28.22 billion$2.61 billion55.25
Teleflex logo
TFX
Teleflex
1.7$362.35-3.3%$16.82 billion$2.60 billion31.00
Hologic logo
HOLX
Hologic
1.7$59.43-3.2%$15.56 billion$3.37 billion25.95Analyst Report
Steris logo
STE
Steris
1.8$157.59-2.7%$13.39 billion$3.03 billion33.04Analyst Downgrade
Insulet logo
PODD
Insulet
1.4$196.17-1.1%$12.76 billion$738.20 million2,452.43Heavy News Reporting
ABIOMED logo
ABMD
ABIOMED
1.3$276.64-4.4%$12.46 billion$840.88 million62.59Analyst Upgrade
Masimo logo
MASI
Masimo
1.4$224.35-1.7%$12.43 billion$937.84 million60.80
Varian Medical Systems logo
VAR
Varian Medical Systems
1.6$121.73-2.0%$11.05 billion$3.23 billion44.75Upcoming Earnings
Hill-Rom logo
HRC
Hill-Rom
1.8$109.30-0.4%$7.45 billion$2.91 billion50.14
Globus Medical logo
GMED
Globus Medical
1.8$46.01-1.3%$4.72 billion$785.37 million31.73
Integra Lifesciences logo
IART
Integra Lifesciences
1.7$47.16-1.7%$4.24 billion$1.52 billion152.13
Wright Medical Group logo
WMGI
Wright Medical Group
1.3$29.92-1.0%$3.86 billion$920.90 million-40.43Heavy News Reporting
NuVasive logo
NUVA
NuVasive
1.8$56.15-2.5%$3.07 billion$1.17 billion48.83
Integer logo
ITGR
Integer
1.9$67.82-2.2%$2.36 billion$1.26 billion21.26Heavy News Reporting
CONMED logo
CNMD
CONMED
1.8$74.77-2.5%$2.28 billion$955.10 million78.71
AtriCure logo
ATRC
AtriCure
1.4$44.53-3.5%$1.88 billion$230.81 million-37.11
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$27.86-3.2%$1.05 billion$248.02 million-89.87Heavy News Reporting
Cryolife logo
CRY
Cryolife
1.6$18.33-0.2%$691.78 million$276.22 million-141.00
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$30.56-0.2%$619.39 million$459.95 million-122.24Analyst Upgrade
SurModics logo
SRDX
SurModics
1.4$43.53-3.5%$592.26 million$100.08 million88.84
AngioDynamics logo
ANGO
AngioDynamics
2.0$10.69-7.2%$402.03 million$359.48 million8.28Upcoming Earnings
Alphatec logo
ATEC
Alphatec
1.4$4.86-7.4%$327.30 million$113.43 million-4.26Upcoming Earnings
Invacare logo
IVC
Invacare
1.4$6.65-4.8%$245.76 million$927.96 million-5.73Analyst Report
Accuray logo
ARAY
Accuray
1.5$2.12-3.3%$199.14 million$418.79 million106.05
Rockwell Medical logo
RMTI
Rockwell Medical
1.9$1.75-1.7%$127.09 million$61.30 million-3.30Analyst Report
Cyberonics logo
CYBX
Cyberonics
0.6N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.